| Category | Item | Details/statistics | Key sources (author-year) | URL/DOI if available |
|---|---|---|---|---|
| Identifiers / synonyms | Primrose syndrome | Rare autosomal dominant multisystem neurodevelopmental syndrome caused by **ZBTB20** variants; major identifiers include **OMIM 259050** and **MONDO: MONDO_0009798** (pqac-00000002, pqac-00000000) | Arora 2021; OpenTargets | OMIM: https://omim.org/entry/259050 |
| Identifiers / synonyms | Causal gene | **ZBTB20** (**OMIM 606025**), BTB-zinc finger transcriptional repressor; disease-target association supported in curated disease resources (pqac-00000002, pqac-00000000) | Arora 2021; OpenTargets | OMIM: https://omim.org/entry/606025 |
| Identifiers / synonyms | Synonym / Orphanet-linked label | Orphanet-linked disease name: **Intellectual disability - cataracts - calcified pinnae - myopathy**; OpenTargets maps this to **Orphanet_3042** and Primrose syndrome to MONDO_0009798 (pqac-00000000) | OpenTargets | https://platform.opentargets.org |
| Epidemiology | Reported rarity | Review source cites prevalence around **~1:1,000,000 births**; evidence base remains sparse and largely case-report/cohort-based (pqac-00000030) | Głowska-Ciemny 2023 | https://doi.org/10.3390/cancers15174302 |
| Core phenotype | Macrocephaly / head circumference >2 SD | **29/38 (76%)** in 42-patient cohort; often postnatal overgrowth pattern (pqac-00000008) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Core phenotype | Intellectual disability | Moderate-severe ID in **33/39 (85%)**; overall literature review also notes all 57 compared patients had ID and/or psychomotor delay (pqac-00000008, pqac-00000007) | Melis 2020; Juven 2020 | https://doi.org/10.1111/cge.13749 ; https://doi.org/10.1038/s41431-020-0582-3 |
| Core phenotype | Autism / behavioral abnormalities | Autism reported in **20/33 (61%)**; severe neurobehavioral dysregulation can occur in adolescence (pqac-00000008, pqac-00000014) | Melis 2020; Moon 2024 | https://doi.org/10.1111/cge.13749 ; https://doi.org/10.1002/ajmg.a.63610 |
| Core phenotype | Hypotonia | **26/34 (76%)** in cohort, typically early-life/childhood manifestation (pqac-00000008) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Core phenotype | Ptosis / facial gestalt | Ptosis in **20/28 (71%)**; characteristic face includes deep-set eyes, ptosis, narrow/downslanting palpebral fissures, depressed nasal bridge (pqac-00000008, pqac-00000003) | Melis 2020; Soğukpınar 2024 | https://doi.org/10.1111/cge.13749 ; https://doi.org/10.1159/000537952 |
| Core phenotype | Hearing loss | Common and often prelingual; GeneReviews-style summary: **21/27 children** and **12/13 adults** affected; missense cases more frequently affected than deletion/truncating groups (pqac-00000013, pqac-00000049) | Arora 2021; Juven 2020 | GeneReviews chapter; https://doi.org/10.1038/s41431-020-0582-3 |
| Core phenotype | External ear calcification | **14/28 (50%)** overall, but **12/12 (100%) adults** in cohort where assessed; highly age-dependent (pqac-00000008) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Core phenotype | Seizures | **6/29 (21%)** in cohort (pqac-00000008) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Age of onset / progression | Cardinal progressive features | Calcified ears, cystic bone lesions, muscle wasting, and contractures typically emerge **between 10 and 16 years**; syndrome is progressive somatically but cognition does not clearly worsen (pqac-00000035, pqac-00000064) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Age of onset / progression | Muscle wasting / contractures | Muscle wasting first noted around **11 years** and contractures around **10 years**, both increasing with age (pqac-00000034, pqac-00000065) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Biochemical markers | Elevated alpha-fetoprotein (AFP) | Elevated in **9/18 (50%)** overall; subgroup breakdown **4/11 (36%)** and **5/7 (71%)**; reported as often persistent over time (pqac-00000031, pqac-00000034) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Biochemical markers | AFP mechanism | Proposed mechanism: **ZBTB20 normally represses hepatic AFP transcription**; loss/dysfunction may “unblock” AFP synthesis (pqac-00000030, pqac-00000039) | Głowska-Ciemny 2023 | https://doi.org/10.3390/cancers15174302 |
| Biochemical markers | Anemia | **5/21 (24%)** overall; subgroup counts **4/16 (25%)** and **1/5 (20%)** (pqac-00000034) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Biochemical markers | Glucose dysregulation | Disturbed glucose metabolism is a cardinal biochemical feature; adults may develop diabetes requiring oral agents and/or insulin (pqac-00000036, pqac-00000055) | Melis 2020; Arora 2021 | https://doi.org/10.1111/cge.13749 ; GeneReviews chapter |
| Biochemical markers | Metabolic profiling / FAO signature | Abnormal acylcarnitines and urine organic acids reported in some patients, suggesting **disturbed mitochondrial fatty-acid oxidation** (pqac-00000034, pqac-00000035) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Recent case report (2023) | Prenatal diagnosis with novel truncating variant | Fetal US/MRI showed corpus callosum agenesis/colpocephaly; fetal exome identified **heterozygous c.1038dup (p.Ile347AspfsTer23)**, de novo/likely pathogenic; highlights prenatal genomic diagnosis (pqac-00000006, pqac-00000050) | Long 2023 | https://doi.org/10.7759/cureus.46546 |
| Recent case report (2024) | Sertraline for severe neurobehavioral symptoms | 17-year-old with de novo **c.1916G>A (p.C639Y)** had aggression, irritability, mood lability refractory to guanfacine/aripiprazole; **sertraline 25 mg/day** led to marked resolution within **2 weeks**, later increased to 50 mg/day, with benefit persisting **>2 years** (pqac-00000009, pqac-00000014) | Moon 2024 | https://doi.org/10.1002/ajmg.a.63610 |
| Recent case report (2024) | Cochlear implantation | Child with Primrose syndrome and bilateral sensorineural hearing loss underwent unilateral **Nucleus CI422** implantation at age 2 after failed 6-month hearing-aid trial; at **3 months** post-op free-field PTA **40 dB**, basic 1–3 word sentences, near-continuous device use (pqac-00000012, pqac-00000057) | Tuğci 2024 | https://doi.org/10.4274/tao.2023.2023-4-5 |
| Recent case report (2024) | Novel infant presentation | 14-month-old girl with de novo **c.1948A>C (p.Asn650His)**; hearing loss and neurodevelopmental findings present before classic later-onset features such as ear calcification or muscle atrophy (pqac-00000003) | Soğukpınar 2024 | https://doi.org/10.1159/000537952 |
| Recent case report (2024) | First Chinese case / ACMG-classified variant | 5-year-old boy with agenesis of corpus callosum, macrocephaly, motor/speech delay, mild ID, autistic behavior; trio WES found de novo **c.1927T>A (p.F643I)** in Zn-finger domain, ACMG **likely pathogenic** (PS2+PM2_supporting+PP3+PP4) (pqac-00000022, pqac-00000047) | Li 2024 | https://doi.org/10.1002/mgg3.2304 |
| Management / surveillance | Standard care model | Multidisciplinary supportive care: speech/OT/PT, developmental services, annual audiology, annual fasting/postprandial glucose and HbA1c (starting ~age 7 or earlier if indicated), thyroid assessment, seizure and musculoskeletal monitoring; no disorder-specific guidelines yet (pqac-00000053, pqac-00000059) | Arora 2021 | GeneReviews chapter |


*Table: This table condenses high-yield identifiers, phenotype frequencies, biochemical markers, and recent 2023-2024 case reports for Primrose syndrome. It is designed as a quick-reference artifact for knowledge base curation and evidence-backed clinical summary writing.*